Drugs / Trofosfamide
Trofosfamide
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01614301 | May 2012 → May 2014 | melanoma | University of Regensburg | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00204568 | Aug 2004 → Oct 2013 | soft tissue sarcoma | University Hospital Schleswig-Holstein | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00749723 | Feb 2006 → Jan 2015 | ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumor | University Hospital, Bonn | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00876031 | Jul 2009 → Jun 2022 | soft tissue sarcoma | University Hospital Tuebingen | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trofosfamide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01614301 ↗ |
| Known as | A-4828 | ChEMBL registry synonym — accepted as the source's own label CHEMBL462019 ↗ |
| Known as | Ixoten | “Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory acting therapy” NCT01614301 ↗ |
| Known as | NSC-109723 | ChEMBL registry synonym — accepted as the source's own label CHEMBL462019 ↗ |
| Known as | Trofosfamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL462019 ↗ |
| Known as | Z-4828 | ChEMBL registry synonym — accepted as the source's own label CHEMBL462019 ↗ |
| Modality | Small molecule | — CHEMBL462019 ↗ |
| Route | Oral | “oral continuous (metronomic) therapy with trofosfamide” NCT00204568 ↗ |